Valuation dashboard for Inovio Pharmaceuticals, Inc. (INO) with P/E N/A, P/B 2.72, EV/EBITDA -0.57 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen.
Analysis Summary
Inovio Pharmaceuticals, Inc. reported revenue of $65343 in the most recent fiscal year, growing at a 5-year CAGR of -61.2%.
Trailing-twelve-month margins: gross margin 100.0%, operating margin -1328.7%, net margin -1300.0%.
At the current price of $1.15, INO has negative trailing earnings (P/E not meaningful) and an ROE of -352.53%. Market capitalisation stands at $79M.
Balance sheet quality for INO: current ratio of 1.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.72 |
| EV / EBITDA | -0.57 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| INO | Inovio Pharmaceuticals, Inc. | $79M | 2.72 | -352.5% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.15 |
| Market Cap | $79M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -352.53% |
| Return on Invested Capital | -259.45% |
| Return on Assets | -114.31% |
| Gross Margin | 100.00% |
| Operating Margin | -132871.32% |
| Net Margin | -130000.00% |
Related companies: ABOS · ACTU · AGEN · ALEC · FATE · IRD · MCRB
Explore sector: Healthcare · Biotechnology
More sections of INO: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks